☰

Seneca Rosenberg, Ph.D. - Publications

Affiliations: 
2012 Educational Studies University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Education, Education Policy, Practice of Teaching
Tree Info Similar researchers PubMed Report error

219 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Seitter SJ, Sherry RM, Yang JC, Robbins PF, Shindorf ML, Copeland AR, McGowan CT, Epstein M, Shelton TE, Langhan MM, Franco Z, Danforth DN, White DE, Rosenberg SA, Goff SL. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34413159 DOI: 10.1158/1078-0432.CCR-21-1171  0.3
2021 Lu YC, Zheng Z, Lowery FJ, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA. Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. Journal For Immunotherapy of Cancer. 9. PMID 34321276 DOI: 10.1136/jitc-2021-002595  0.309
2021 Leko V, Cafri G, Yossef R, Paria B, Hill V, Gurusamy D, Zheng Z, Gartner JJ, Prickett TD, Goff SL, Robbins P, Lu YC, Rosenberg SA. Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma. Journal For Immunotherapy of Cancer. 9. PMID 34266885 DOI: 10.1136/jitc-2021-002882  0.353
2020 Leko V, Rosenberg SA. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Cancer Cell. PMID 32822573 DOI: 10.1016/j.ccell.2020.07.013  0.321
2020 Rosenberg S. Abstract IA24: T cells as a drug for the personalized immunotherapy of cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm19-Ia24  0.333
2020 Krishna S, Lowery F, Copeland A, Goff S, Altan-Bonnet G, Robbins P, Rosenberg S. 773 Adoptive Cell Therapy Response in Melanoma is Mediated by Stem-like CD8 T cells Journal For Immunotherapy of Cancer. 8: A822-A822. DOI: 10.1136/jitc-2020-sitc2020.0773  0.309
2020 Palmer D, Webber B, Patel Y, Johnson M, Kariya C, Lahr W, Parkhurst M, Gartner J, Prickett T, Lowery F, Kishton R, Gurusamy D, Franco Z, Vodnala S, Diers M, ... ... Rosenberg S, et al. 333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program Journal For Immunotherapy of Cancer. 8: A359-A359. DOI: 10.1136/jitc-2020-sitc2020.0333  0.325
2019 Lu YC, Jia L, Zheng Z, Tran E, Robbins PF, Rosenberg SA. Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy. Cancer Immunology Research. PMID 31484655 DOI: 10.1158/2326-6066.CIR-19-0299  0.31
2019 Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, Crystal JS, Sachs A, Groh EM, Ray S, Ngo LT, ... ... Rosenberg SA, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discovery. PMID 31164343 DOI: 10.1158/2159-8290.CD-18-1494  0.321
2019 Leko V, McDuffie LA, Zheng Z, Gartner JJ, Prickett TD, Apolo AB, Agarwal PK, Rosenberg SA, Lu YC. Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer. Journal of Immunology (Baltimore, Md. : 1950). PMID 31036766 DOI: 10.4049/jimmunol.1801022  0.309
2019 Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, ... ... Rosenberg SA, et al. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 30882547 DOI: 10.1097/Cji.0000000000000260  0.314
2019 Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Restifo NP, Sachs A, Tran E, Lo W, Somerville RP, Rosenberg SA, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. The Journal of Clinical Investigation. PMID 30714987 DOI: 10.1172/Jci123791  0.303
2019 Cafri G, Yossef R, Pasetto A, Deniger DC, Lu YC, Parkhurst M, Gartner JJ, Jia L, Ray S, Ngo LT, Jafferji M, Sachs A, Prickett T, Robbins PF, Rosenberg SA. Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients. Nature Communications. 10: 449. PMID 30683863 DOI: 10.1038/s41467-019-08304-z  0.312
2019 Ahmadzadeh M, Pasetto A, Jia L, Deniger DC, Stevanović S, Robbins PF, Rosenberg SA. Tumor-infiltrating human CD4 regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Science Immunology. 4. PMID 30635355 DOI: 10.1126/sciimmunol.aao4310  0.348
2019 Rosenberg SA. Abstract IA14: Cell transfer immunotherapy targeting unique somatic mutations in cancer Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-Ia14  0.324
2019 Yossef R, Tran E, Gros A, Deniger D, Cafri G, Rosenberg SA. Abstract B055: Enhanced detection of T-cells targeting unique neoantigens and shared mutated oncogenes for personalized cancer immunotherapy Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B055  0.351
2018 Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. Jci Insight. 3. PMID 30282837 DOI: 10.1172/jci.insight.122467  0.353
2018 Samuels Y, Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, ... ... Rosenberg SA, et al. Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma. Cancer Discovery. PMID 30209080 DOI: 10.1158/2159-8290.Cd-17-1418  0.327
2018 Brudno J, Hartman S, Lam N, Stroncek DF, Rossi JM, Shen Y, Xue A, Bot A, Kanakry JA, Pavletic SZ, Mikkilineni L, Roschewski M, Dean RM, Rose JJ, Patel R, ... ... Rosenberg SA, et al. Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR Blood. 132: 697-697. DOI: 10.1182/BLOOD-2018-99-113731  0.303
2017 Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, Fitzgerald PC, Rosenberg SA. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29174843 DOI: 10.1016/j.ymthe.2017.10.018  0.335
2017 Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, ... ... Rosenberg SA, et al. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017745463. PMID 28809608 DOI: 10.1200/JCO.2017.74.5463  0.345
2017 Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science (New York, N.Y.). 356: 200-205. PMID 28408606 DOI: 10.1126/Science.Aak9510  0.342
2017 Kochenderfer JN, Somerville RP, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, ... ... Rosenberg SA, et al. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016713024. PMID 28291388 DOI: 10.1200/Jco.2016.71.3024  0.316
2017 Hinrichs CS, Doran SL, Stevanovic S, Adhikary S, Mojadidi M, Kwong ML, Faquin WC, Feldman S, Somerville R, Sherry RM, Yang JC, Rosenberg SA. A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers. Journal of Clinical Oncology. 35: 3009-3009. DOI: 10.1200/JCO.2017.35.15_SUPPL.3009  0.34
2017 Zacharakis N, Trebska-McGowan K, Somerville R, Lu Y, Pasetto A, Black M, Chinnasamy H, Xu H, Gartner JJ, Prickett TD, Robbins PF, Rosenberg SA, Goff SL, Feldman SA. Abstract 4982: Regression of metastatic breast cancer after adoptive cell transfer of tumor infiltrating lymphocytes and checkpoint blockade Cancer Research. 77: 4982-4982. DOI: 10.1158/1538-7445.Am2017-4982  0.336
2017 Rossi J, Paczkowski P, Shen Y, Morse K, Flynn B, Kaiser A, Ng C, Gallatin K, Cain T, Fan R, Mackay S, Heath J, Rosenberg SA, Kochenderfer JN, Zhou J, et al. Abstract 2990: Polyfunctional anti-CD19 CAR T cells determined by single-cell multiplex proteomics associated with clinical activity in patients with advanced non-Hodgkin’s lymphoma Cancer Research. 77: 2990-2990. DOI: 10.1158/1538-7445.Am2017-2990  0.301
2016 Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. The New England Journal of Medicine. 375: 2255-2262. PMID 27959684 DOI: 10.1056/NEJMoa1609279  0.328
2016 Pasetto A, Alena G, Robbins PF, Deniger DC, Prickett TD, Matus-Nicodemos R, Douek DC, Howie B, Robins H, Parkhurst MR, Gartner JJ, Trebska-McGowan K, Crystal JS, Rosenberg SA. Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor. Cancer Immunology Research. PMID 27354337 DOI: 10.1158/2326-6066.Cir-16-0001  0.348
2016 Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research. PMID 27312342 DOI: 10.1158/2326-6066.CIR-15-0215  0.355
2016 Yao X, Lu YC, Parker LL, Li YF, El-Gamil M, Black MA, Xu H, Feldman SA, van der Bruggen P, Rosenberg SA, Robbins PF. Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 39: 191-201. PMID 27163739 DOI: 10.1097/CJI.0000000000000123  0.325
2016 Deniger DC, Pasetto A, Tran E, Parkhurst MR, Cohen CJ, Robbins PF, Cooper LJ, Rosenberg SA. Stable, non-viral expression of mutated tumor neoantigen-specific T-cell receptors using the Sleeping Beauty transposon/transposase system. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26945006 DOI: 10.1038/mt.2016.51  0.317
2016 Jaigirdar A, Rosenberg SA, Parkhurst M. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 26938944 DOI: 10.1097/CJI.0000000000000116  0.335
2016 Yang JC, Rosenberg SA. Adoptive T-Cell Therapy for Cancer. Advances in Immunology. 130: 279-294. PMID 26923004 DOI: 10.1016/bs.ai.2015.12.006  0.328
2016 Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nature Medicine. PMID 26901407 DOI: 10.1038/nm.4051  0.302
2016 Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine. 22: 26-36. PMID 26735408 DOI: 10.1038/Nm.4015  0.324
2016 Kochenderfer J, Somerville R, Lu T, Shi V, Yang JC, Sherry R, Klebanoff C, Kammula US, Goff SL, Bot A, Rossi J, Sherman M, Perez A, Xue A, Feldman TA, ... ... Rosenberg SA, et al. Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma. Journal of Clinical Oncology. 34: LBA3010-LBA3010. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba3010  0.318
2016 Prickett TD, Crystal J, Gartner J, Yao X, Pasetto A, Gros A, Lu Y, Li YF, El-Gamil M, Rosenberg SA, Robbins P. Abstract PR002: Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Pr002  0.364
2016 Rosenberg S. Abstract IA01: T cells as a drug for the personalized immunotherapy of cancer Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-Ia01  0.332
2016 Lu Y, Parker LL, Lu T, Zheng Z, Yao X, Robbins PF, Feldman SA, Bruggen Pvd, Klebanoff CA, Hinrichs CS, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Abstract CT003: A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct003  0.365
2016 Deniger DC, Pasetto A, Prickett TD, Gartner JJ, Bharathan M, Tran E, Robbins PF, Rosenberg SA. 391. Mutated Tumor Neoantigens Are Recognized by Tumor Infiltrating Lymphocytes from Metastatic Ovarian Cancer Molecular Therapy. 24: S155. DOI: 10.1016/S1525-0016(16)33200-2  0.329
2016 Pasetto A, Gros A, Robbins PF, Deniger DC, Prickett TD, Parkhurst MR, Matus-Nicodemos R, Douek DC, Gartner J, Trebska-McGowan K, Crystal J, Rosenberg SA. 272. Rapid Identification of Tumor- and Neoantigen-Reactive T-Cell Receptors for Personalized Immunotherapy Molecular Therapy. 24: S108. DOI: 10.1016/S1525-0016(16)33081-7  0.345
2015 Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, Wunderlich JR, Somerville RP, Rosenberg SA. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science (New York, N.Y.). PMID 26516200 DOI: 10.1126/science.aad1253  0.317
2015 Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. The Journal of Clinical Investigation. PMID 26389673 DOI: 10.1172/JCI82416  0.337
2015 Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA. Adoptive Cell Therapy-Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. Seminars in Oncology. 42: 626-39. PMID 26320066 DOI: 10.1053/j.seminoncol.2015.05.005  0.374
2015 Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, N.Y.). 348: 62-8. PMID 25838374 DOI: 10.1126/Science.Aaa4967  0.303
2015 Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, ... ... Rosenberg SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1019-27. PMID 25538264 DOI: 10.1158/1078-0432.Ccr-14-2708  0.36
2015 Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 534-43. PMID 25424856 DOI: 10.1158/1078-0432.Ccr-14-2208  0.353
2015 Cohen C, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-Mcgowan K, Bliskovsky V, Parkhurst MR, Ankri C, Prickett TD, Crystal J, Li Y, El-Gamil M, Rosenberg SA, Robbins PF. Study and characterization of mutated antigen specific T cells isolated from fresh tumor and peripheral lymphocytes in cancer patients Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P7  0.35
2015 Stevanović S, Anna P, Gartner JJ, Tran E, Robbins PF, Rosenberg SA, Hinrichs CS. Adoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P52  0.314
2015 Bharathan M, Trebska-McGowan K, Anna P, Deniger DC, Hanada K, Gartner JJ, Yang JC, Rosenberg SA, Robbins PF. Tetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers Journal For Immunotherapy of Cancer. 3: 47. DOI: 10.1186/2051-1426-3-S2-P47  0.325
2015 Anna P, Gros A, Robbins PF, Prickett TD, Deniger DC, Matus-Nicodemus R, Parkhurst MR, Crystal JS, Trebska-Mcgowan K, Rosenberg SA. High frequency CD8+PD-1+ TCR clonotypes isolated from fresh melanomas display anti-tumor activity Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P42  0.32
2015 Parkhurst M, Gros A, Anna P, Tran E, Crystal JS, Prickett T, Robbins P, Rosenberg SA. Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P40  0.321
2015 Hanada K, Chow C, Hoyos RG, Gartner JJ, Prickett TD, Somerville R, Hogan K, Robbins PF, Rosenberg SA, Yang JC. Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P20  0.303
2015 Prickett TD, Crystal JS, Gartner JJ, Xin Y, Anna P, Gros A, Lu Y, Li Y, El-Gamil M, Rosenberg SA, Robbins P. Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-O4  0.353
2015 Rosenberg SA. Abstract IA19: Curative potential of T-cell immunotherapy for cancer Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-Ia19  0.343
2015 Crystal JS, Prickett T, Lu Y, Gartner JJ, Parkhurst M, Gros A, Li YF, El-Gamil M, Rosenberg SA, Robbins PF. Abstract LB-221: Diversity of tumor infiltrating lymphocyte recognition of diverse mutated antigens in cutaneous melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-221  0.313
2014 Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M. Specific increase in potency via structure-based design of a TCR. Journal of Immunology (Baltimore, Md. : 1950). 193: 2587-99. PMID 25070852 DOI: 10.4049/Jimmunol.1302344  0.313
2014 Tran E, Rosenberg SA. T-cell therapy against cancer mutations. Oncotarget. 5: 4579-80. PMID 25046408 DOI: 10.18632/Oncotarget.2234  0.313
2014 Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3401-10. PMID 24987109 DOI: 10.1158/1078-0432.CCR-14-0433  0.353
2014 Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. Journal of Immunology (Baltimore, Md. : 1950). 192: 5451-8. PMID 24907378 DOI: 10.4049/jimmunol.1490019  0.302
2014 Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (New York, N.Y.). 344: 641-5. PMID 24812403 DOI: 10.1126/science.1251102  0.323
2014 Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, Feldman SA, Rosenberg SA, Morgan RA. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer. Plos One. 9: e93321. PMID 24681846 DOI: 10.1371/journal.pone.0093321  0.366
2014 Rosati SF, Parkhurst MR, Hong Y, Zheng Z, Feldman SA, Rao M, Abate-Daga D, Beard RE, Xu H, Black MA, Robbins PF, Schrump DA, Rosenberg SA, Morgan RA. A novel murine T-cell receptor targeting NY-ESO-1. Journal of Immunotherapy (Hagerstown, Md. : 1997). 37: 135-46. PMID 24598449 DOI: 10.1097/CJI.0000000000000019  0.334
2014 Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Therapy. 21: 45-7. PMID 24535159 DOI: 10.1038/cgt.2014.3  0.341
2014 Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunological Reviews. 257: 56-71. PMID 24329789 DOI: 10.1111/imr.12132  0.37
2014 Turcotte S, Gros A, Tran E, Lee CC, Wunderlich JR, Robbins PF, Rosenberg SA. Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 331-43. PMID 24218514 DOI: 10.1158/1078-0432.CCR-13-1736  0.353
2014 Better M, Pugach O, Lu L, Somerville R, Kassim S, Kochenderfer J, Rosenberg SA, Marshall MA, Bot A, Nolop KB, Roberts M, Feldman S. Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR. Journal of Clinical Oncology. 32: 3079-3079. DOI: 10.1200/Jco.2014.32.15_Suppl.3079  0.325
2014 Malecek K, Grigoryan A, Zhong S, Gu WJ, Johnson LA, Rosenberg SA, Cardozo T, Krogsgaard M. Specific increase in T-cell potency via structure-based design of a T-cell receptor for adoptive immunotherapy. Journal of Clinical Oncology. 32: 3063-3063. DOI: 10.1200/Jco.2014.32.15_Suppl.3063  0.335
2014 Crystal JS, Lu YC, Li Y, El-Gamil M, Prickett T, Trebska-McGowan K, Cohen C, Rosenberg SA, Robbins PF. Individual cultures of melanoma tumor infiltrating lymphocytes possess distinct patterns of reactivity with mutated antigens identified by whole exome sequencing of autologous tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P8  0.311
2014 Parkhurst M, Robbins P, Rosenberg S. Isolation of T cell receptors specifically reactive with mutated tumor associated antigens Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P33  0.317
2014 Lee DW, Stetler-Stevenson M, Sabatino M, Yuan C, Fry TJ, Shah NN, Delbrook C, Yates B, Zhang H, Zhang L, Tschernia N, Cui Y, Feldman S, Kochenderfer JN, Rosenberg SA, et al. Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia Blood. 124: 381-381. DOI: 10.1182/Blood.V124.21.381.381  0.313
2013 Phan GQ, Rosenberg SA. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer Control : Journal of the Moffitt Cancer Center. 20: 289-97. PMID 24077405 DOI: 10.1177/107327481302000406  0.351
2013 Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, ... ... Rosenberg SA, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 122: 4129-39. PMID 24055823 DOI: 10.1182/Blood-2013-08-519413  0.318
2013 Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 191: 2217-25. PMID 23904171 DOI: 10.4049/jimmunol.1300538  0.373
2013 Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. The Journal of Experimental Medicine. 210: 1125-35. PMID 23712432 DOI: 10.1084/Jem.20130110  0.309
2013 Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. Journal of Immunology (Baltimore, Md. : 1950). 190: 6034-42. PMID 23690473 DOI: 10.4049/jimmunol.1202830  0.342
2013 Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, ... ... Rosenberg SA, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2152-9. PMID 23650429 DOI: 10.1200/Jco.2012.46.6441  0.326
2013 Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine. 19: 747-52. PMID 23644516 DOI: 10.1038/nm.3161  0.302
2013 Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Research. 73: 3371-80. PMID 23633494 DOI: 10.1158/0008-5472.Can-12-3913  0.329
2013 Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1369-77. PMID 23568260 DOI: 10.1038/Mt.2013.58  0.31
2013 Lee DW, Shah NN, Stetler-Stevenson M, Sabatino M, Delbrook C, Richards K, Kochenderfer JN, Rosenberg SA, Stroncek D, Wayne AS, Mackall CL. Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Blood. 122: 68-68. DOI: 10.1182/blood.v122.21.68.68  0.319
2013 Kochenderfer JN, Dudley ME, Kassim SH, Carpenter RO, Yang JC, Phan GQ, Hughes MS, Sherry RM, Feldman S, Spaner D, Nathan DN, Morton KE, Toomey MA, Rosenberg SA. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor Blood. 122: 168-168. DOI: 10.1182/Blood.V122.21.168.168  0.313
2013 Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford W, Hakim FT, Halverson D, Fowler DH, Hardy NM, Mato A, Hickstein DD, Gea-Banacloche J, Pavletic SZ, Sportes C, ... ... Rosenberg SA, et al. Donor-Derived Anti-CD19 Chimeric-Antigen-Receptor-Expressing T Cells Cause Regression Of Malignancy Persisting After Allogeneic Hematopoietic Stem Cell Transplantation Blood. 122: 151-151. DOI: 10.1182/Blood.V122.21.151.151  0.326
2012 Wang A, Chandran S, Shah SA, Chiu Y, Paria BC, Aghamolla T, Alvarez-Downing MM, Lee CC, Singh S, Li T, Dudley ME, Restifo NP, Rosenberg SA, Kammula US. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Science Translational Medicine. 4: 149ra120. PMID 22932225 DOI: 10.1126/Scitranslmed.3004306  0.317
2012 Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5212-23. PMID 22837179 DOI: 10.1158/1078-0432.CCR-12-1108  0.332
2012 Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, Zhang W, Fine HA, Rosenberg SA. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Human Gene Therapy. 23: 1043-53. PMID 22780919 DOI: 10.1089/hum.2012.041  0.32
2012 Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Science Translational Medicine. 4: 127ps8. PMID 22461638 DOI: 10.1126/scitranslmed.3003634  0.302
2012 Kvistborg P, Shu CJ, Heemskerk B, Fankhauser M, Thrue CA, Toebes M, Van Rooij N, Linnemann C, Van Buuren MM, Urbanus JHM, Beltman JB, Straten P, Li YF, Robbins PF, Besser MJ, ... ... Rosenberg SA, et al. TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients Oncoimmunology. 1: 409-418. DOI: 10.4161/onci.18851  0.321
2012 Turcotte S, Gros A, Wunderlich JR, Hogan K, Wang QJ, Fetsch P, Dudley ME, Rosenberg SA. Study of tumor-infiltrating T-cell reactivity to metastatic gastrointestinal cancers. Journal of Clinical Oncology. 30: e14179-e14179. DOI: 10.1200/jco.2012.30.15_suppl.e14179  0.324
2011 Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA, Restifo NP. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. The Journal of Clinical Investigation. 121: 4746-57. PMID 22056381 DOI: 10.1172/Jci58814  0.338
2011 Friedman KM, Devillier LE, Feldman SA, Rosenberg SA, Dudley ME. Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 651-61. PMID 21989413 DOI: 10.1097/CJI.0b013e31823284c3  0.349
2011 Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Advances in Surgery. 45: 341-60. PMID 21954698 DOI: 10.1016/j.yasu.2011.04.003  0.333
2011 Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6287-97. PMID 21844012 DOI: 10.1158/1078-0432.CCR-11-1347  0.339
2011 Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. Plos One. 6: e22560. PMID 21829468 DOI: 10.1371/journal.pone.0022560  0.31
2011 Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. Nature Reviews. Clinical Oncology. 8: 577-85. PMID 21808266 DOI: 10.1038/nrclinonc.2011.116  0.319
2011 Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5343-52. PMID 21737507 DOI: 10.1158/1078-0432.Ccr-11-0503  0.357
2011 Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends in Biotechnology. 29: 550-7. PMID 21663987 DOI: 10.1016/j.tibtech.2011.04.009  0.338
2011 Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4550-7. PMID 21498393 DOI: 10.1158/1078-0432.Ccr-11-0116  0.321
2011 Yang S, Gattinoni L, Luca G, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunology, Immunotherapy : Cii. 60: 739-49. PMID 21305379 DOI: 10.1007/S00262-011-0977-7  0.315
2011 Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, ... ... Rosenberg SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 917-24. PMID 21282551 DOI: 10.1200/Jco.2010.32.2537  0.39
2011 Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, ... ... Rosenberg SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 620-6. PMID 21157437 DOI: 10.1038/Mt.2010.272  0.336
2011 Kochenderfer JN, Dudley ME, Feldman S, Wilson WH, Spaner D, Devillier L, Carpenter R, Nathan DN, Maric I, Morgan RA, Rosenberg SA. B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor Blood. 118: 167-167. DOI: 10.1182/Blood.V118.21.167.167  0.33
2011 Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, Rosenberg SA, Morgan RA. Erratum to: In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells Cancer Immunology, Immunotherapy. 60: 751-751. DOI: 10.1007/S00262-011-0994-6  0.309
2010 Davis JL, Theoret MR, Zheng Z, Lamers CH, Rosenberg SA, Morgan RA. Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5852-61. PMID 21138872 DOI: 10.1158/1078-0432.CCR-10-1280  0.317
2010 Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. The Journal of Clinical Investigation. 120: 3953-68. PMID 20978347 DOI: 10.1172/Jci43490  0.332
2010 Rosenberg SA. Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1744-5. PMID 20885433 DOI: 10.1038/mt.2010.195  0.333
2010 Morgan RA, Dudley ME, Rosenberg SA. Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer Journal (Sudbury, Mass.). 16: 336-41. PMID 20693844 DOI: 10.1097/PPO.0b013e3181eb3879  0.323
2010 Kalbasi A, Shrimali RK, Chinnasamy D, Rosenberg SA. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 672-83. PMID 20664359 DOI: 10.1097/CJI.0b013e3181e475cd  0.306
2010 Kerkar SP, Muranski P, Kaiser A, Boni A, Sanchez-Perez L, Yu Z, Palmer DC, Reger RN, Borman ZA, Zhang L, Morgan RA, Gattinoni L, Rosenberg SA, Trinchieri G, Restifo NP. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Research. 70: 6725-34. PMID 20647327 DOI: 10.1158/0008-5472.Can-10-0735  0.318
2010 Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Research. 70: 3027-33. PMID 20395199 DOI: 10.1158/0008-5472.Can-09-2824  0.325
2010 Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 843-51. PMID 20179677 DOI: 10.1038/mt.2010.24  0.34
2010 Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 1-7. PMID 19952961 DOI: 10.1097/Cji.0B013E3181B88Ffc  0.319
2010 Kochenderfer JN, Dudley ME, Stetler-Stevenson M, Wilson WH, Janik JE, Nathan DN, Maric I, Raffeld M, Feldman SA, Morgan RA, Rosenberg SA. A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells Blood. 116: 2865-2865. DOI: 10.1182/BLOOD.V116.21.2865.2865  0.326
2009 Smith FO, Klapper JA, Wunderlich JR, Rosenberg SA, Dudley ME. Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 32: 870-4. PMID 19752747 DOI: 10.1097/CJI.0b013e3181b36b69  0.309
2009 Burns WR, Zheng Z, Rosenberg SA, Morgan RA. Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation. Blood. 114: 2888-99. PMID 19589923 DOI: 10.1182/blood-2009-01-199216  0.308
2009 Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, ... ... Rosenberg SA, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 114: 535-46. PMID 19451549 DOI: 10.1182/Blood-2009-03-211714  0.333
2009 Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO, Hampson BS, Rosenberg SA, Dudley ME. Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. Journal of Immunological Methods. 345: 90-9. PMID 19389403 DOI: 10.1016/j.jim.2009.04.009  0.309
2009 Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology. 21: 233-40. PMID 19304471 DOI: 10.1016/j.coi.2009.03.002  0.359
2008 Theoret MR, Cohen CJ, Dudley ME, Morgan RA, Rosenberg SA. In vitro and in vivo studies of human lymphocytes genetically engineered to express T cell receptors that recognize a p53 antigenic epitope. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3032. PMID 27947569 DOI: 10.1200/jco.2008.26.15_suppl.3032  0.348
2008 Theoret MR, Cohen CJ, Nahvi AV, Ngo LT, Suri KB, Powell DJ, Dudley ME, Morgan RA, Rosenberg SA. Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells. Human Gene Therapy. 19: 1219-32. PMID 19848582 DOI: 10.1089/HUM.2008.083  0.311
2008 Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ, Wunderlich JR, Merino MJ, Rosenberg SA. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 112: 4953-60. PMID 18820132 DOI: 10.1182/blood-2008-06-163048  0.33
2008 Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 112: 4746-54. PMID 18799724 DOI: 10.1182/Blood-2008-07-169797  0.313
2008 Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 105: 8061-6. PMID 18523011 DOI: 10.1073/Pnas.0710929105  0.302
2008 Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-cell receptor gene therapy of established tumors in a murine melanoma model. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 1-6. PMID 18157006 DOI: 10.1097/Cji.0B013E31815C193F  0.342
2008 Ahmadzadeh M, Felipe-Silva A, Merino M, Rosenberg S. OR.86. Accumulation of Tumor Infiltrating FOXP3+ CD4+ Regulatory T Cells in Tumors and Not in Peripheral Blood in Patients with Melanoma Clinical Immunology. 127: S35. DOI: 10.1016/j.clim.2008.03.093  0.304
2007 Dudley ME, Rosenberg SA. Adoptive cell transfer therapy. Seminars in Oncology. 34: 524-31. PMID 18083376 DOI: 10.1053/j.seminoncol.2007.09.002  0.344
2007 Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 825-30. PMID 18049334 DOI: 10.1097/CJI.0b013e318156e47e  0.317
2007 Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP. Toll-like receptors in tumor immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5280-9. PMID 17875756 DOI: 10.1158/1078-0432.Ccr-07-1378  0.325
2007 Powell DJ, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 438-47. PMID 17457218 DOI: 10.1097/CJI.0b013e3180600ff9  0.33
2007 Zhao Y, Parkhurst MR, Zheng Z, Cohen CJ, Riley JP, Gattinoni L, Restifo NP, Rosenberg SA, Morgan RA. Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. Cancer Research. 67: 2425-9. PMID 17363559 DOI: 10.1158/0008-5472.Can-06-3977  0.341
2007 Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. The Journal of Clinical Investigation. 117: 492-501. PMID 17273561 DOI: 10.1172/Jci30414  0.32
2006 Johnson LA, Heemskerk B, Powell DJ, Cohen CJ, Morgan RA, Dudley ME, Robbins PF, Rosenberg SA. Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 177: 6548-59. PMID 17056587 DOI: 10.4049/Jimmunol.177.9.6548  0.345
2006 Powell DJ, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of Immunology (Baltimore, Md. : 1950). 177: 6527-39. PMID 17056585 DOI: 10.4049/Jimmunol.177.9.6527  0.319
2006 Grover A, Kim GJ, Lizée G, Tschoi M, Wang G, Wunderlich JR, Rosenberg SA, Hwang ST, Hwu P. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5801-8. PMID 17020987 DOI: 10.1158/1078-0432.Ccr-05-2421  0.33
2006 Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, ... Rosenberg SA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (New York, N.Y.). 314: 126-9. PMID 16946036 DOI: 10.1126/Science.1129003  0.342
2006 Jones S, Hsu C, Morgan R, Rosenberg S. 767. Genetic Engineering of an Immortal Human CD8+ T Cell Line Molecular Therapy. 13: S297. DOI: 10.1016/j.ymthe.2006.08.852  0.352
2006 Zhao Y, Zheng Z, Cohen CJ, Rosenberg SA, Morgan RA. 454. Recognition of Tumor Antigens by In Vitro Developed T Cells from Hematopoietic Stem Cells Retrovirally Transduced with TCR Genes Molecular Therapy. 13: S175. DOI: 10.1016/j.ymthe.2006.08.522  0.301
2006 Rosenberg SA, Restifo NP. Response to comment on "tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma" [2] Journal of Immunology. 176: 4511-4512.  0.319
2005 Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Annals of Surgical Oncology. 12: 1005-16. PMID 16283570 DOI: 10.1245/ASO.2005.03.536  0.352
2005 Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 175: 7046-52. PMID 16272366 DOI: 10.4049/Jimmunol.175.10.7046  0.316
2005 Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 175: 6169-76. PMID 16237114 DOI: 10.4049/Jimmunol.175.9.6169  0.324
2005 Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 593-8. PMID 16224277 DOI: 10.1097/01.Cji.0000178913.41256.06  0.305
2005 Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 582-92. PMID 16224276 DOI: 10.1097/01.Cji.0000175468.19742.10  0.31
2005 Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesinski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. The Journal of Experimental Medicine. 202: 907-12. PMID 16203864 DOI: 10.1084/Jem.20050732  0.322
2005 Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 9571-6. PMID 15980149 DOI: 10.1073/Pnas.0503726102  0.313
2005 Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. The Journal of Clinical Investigation. 115: 1616-26. PMID 15931392 DOI: 10.1172/Jci24480  0.338
2005 Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA. Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Human Gene Therapy. 16: 457-72. PMID 15871677 DOI: 10.1089/hum.2005.16.457  0.342
2005 Rosenberg SA. The emergence of modern cancer immunotherapy. Annals of Surgical Oncology. 12: 344-6. PMID 15843873 DOI: 10.1245/ASO.2005.01.904  0.328
2005 Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 258-67. PMID 15838383 DOI: 10.1097/01.Cji.0000158855.92792.7A  0.31
2005 Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. Journal of Immunology (Baltimore, Md. : 1950). 174: 4415-23. PMID 15778407 DOI: 10.4049/Jimmunol.174.7.4415  0.316
2005 Charo J, Finkelstein SE, Grewal N, Restifo NP, Robbins PF, Rosenberg SA. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Research. 65: 2001-8. PMID 15753400 DOI: 10.1158/0008-5472.Can-04-2006  0.342
2005 Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 53-62. PMID 15614045 DOI: 10.1097/00002371-200501000-00007  0.36
2005 Powell DJ, Dudley ME, Robbins PF, Rosenberg SA. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood. 105: 241-50. PMID 15345595 DOI: 10.1182/blood-2004-06-2482  0.333
2004 Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 173: 7622-9. PMID 15585890 DOI: 10.4049/Jimmunol.173.12.7622  0.344
2004 Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. Journal of Immunology (Baltimore, Md. : 1950). 173: 7125-30. PMID 15585832 DOI: 10.4049/Jimmunol.173.12.7125  0.35
2004 Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 478-9. PMID 15534492 DOI: 10.1097/00002371-200411000-00008  0.313
2004 Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proceedings of the National Academy of Sciences of the United States of America. 101: 14639-45. PMID 15381769 DOI: 10.1073/pnas.0405730101  0.354
2004 Finkelstein SE, Heimann DM, Klebanoff CA, Antony PA, Gattinoni L, Hinrichs CS, Hwang LN, Palmer DC, Spiess PJ, Surman DR, Wrzesiniski C, Yu Z, Rosenberg SA, Restifo NP. Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology. 76: 333-7. PMID 15155774 DOI: 10.1189/Jlb.0304120  0.354
2004 Huang J, El-Gamil M, Dudley ME, Li YF, Rosenberg SA, Robbins PF. T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. Journal of Immunology (Baltimore, Md. : 1950). 172: 6057-64. PMID 15128789 DOI: 10.4049/Jimmunol.172.10.6057  0.301
2004 Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 184-90. PMID 15076135 DOI: 10.1097/00002371-200405000-00002  0.316
2003 Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 26: 385-93. PMID 12973027 DOI: 10.1097/00002371-200309000-00001  0.349
2003 Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, ... ... Rosenberg SA, et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. The Journal of Experimental Medicine. 198: 569-80. PMID 12925674 DOI: 10.1084/Jem.20030590  0.327
2003 Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, ... ... Rosenberg SA, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America. 100: 8372-7. PMID 12826605 DOI: 10.1073/Pnas.1533209100  0.315
2002 Robbins PF, El-Gamil M, Li YF, Zeng G, Dudley M, Rosenberg SA. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma. Journal of Immunology (Baltimore, Md. : 1950). 169: 6036-47. PMID 12421991 DOI: 10.4049/jimmunol.169.10.6036  0.319
2002 Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, ... ... Rosenberg SA, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, N.Y.). 298: 850-4. PMID 12242449 DOI: 10.1126/Science.1076514  0.354
2002 Harada M, Li YF, El-Gamil M, Ohnmacht GA, Rosenberg SA, Robbins PF. Melanoma-Reactive CD8+ T cells recognize a novel tumor antigen expressed in a wide variety of tumor types. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 323-33. PMID 11565834 DOI: 10.1097/00002371-200107000-00008  0.301
2001 Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 24: 363-73. PMID 11565838 DOI: 10.1097/00002371-200107000-00012  0.351
2001 Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proceedings of the National Academy of Sciences of the United States of America. 98: 3964-9. PMID 11259659 DOI: 10.1073/pnas.061507398  0.309
2001 Fritsch M, Rosenberg SA, Duray PH. Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine. Journal of Immunotherapy (Hagerstown, Md. : 1997). 23: 557-69. PMID 11001549 DOI: 10.1097/00002371-200009000-00006  0.32
2000 Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, Hwu P. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Human Gene Therapy. 11: 2377-87. PMID 11096442 DOI: 10.1089/104303400750038480  0.356
2000 Zeng G, Touloukian CE, Wang X, Restifo NP, Rosenberg SA, Wang RF. Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. Journal of Immunology (Baltimore, Md. : 1950). 165: 1153-9. PMID 10878395 DOI: 10.4049/Jimmunol.165.2.1153  0.301
2000 Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM. Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. Journal of Immunology (Baltimore, Md. : 1950). 164: 495-504. PMID 10605047 DOI: 10.4049/jimmunol.164.1.495  0.323
1999 Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunological Reviews. 170: 85-100. PMID 10566144 DOI: 10.1111/j.1600-065X.1999.tb01331.x  0.339
1999 Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. The Journal of Experimental Medicine. 189: 1659-68. PMID 10330445 DOI: 10.1084/jem.189.10.1659  0.3
1999 Pieper R, Christian RE, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. The Journal of Experimental Medicine. 189: 757-66. PMID 10049939 DOI: 10.1084/Jem.189.5.757  0.323
1998 Nishimura MI, Custer MC, Schwarz SL, Parker LL, Mixon A, Clay TM, Yannelli JR, Rosenberg SA. T cell-receptor V gene use by CD4+ melanoma-reactive clonal and oligoclonal T-cell lines. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 352-62. PMID 9789197 DOI: 10.1097/00002371-199809000-00003  0.323
1998 Kawakami Y, Robbins PF, Wang RF, Parkhurst M, Kang X, Rosenberg SA. The use of melanosomal proteins in the immunotherapy of melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 21: 237-46. PMID 9672845 DOI: 10.1097/00002371-199807000-00001  0.342
1998 Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nature Medicine. 4: 168-72. PMID 9461189 DOI: 10.1038/NM0298-168  0.308
1997 Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunologic Research. 16: 313-39. PMID 9439758 DOI: 10.1007/BF02786397  0.349
1997 Kawakami Y, Rosenberg SA. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. International Reviews of Immunology. 14: 173-92. PMID 9131386 DOI: 10.3109/08830189709116851  0.323
1997 Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, Rosenberg SA, Yang JC. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. The Journal of Experimental Medicine. 185: 453-9. PMID 9053445 DOI: 10.1084/JEM.185.3.453  0.305
1997 Mulé JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Human Gene Therapy. 7: 1545-53. PMID 8864755 DOI: 10.1089/HUM.1996.7.13-1545  0.325
1996 Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens Journal of the National Cancer Institute. 88: 1635-1644. PMID 8931607 DOI: 10.1093/jnci/88.22.1635  0.303
1996 Wang RF, Rosenberg SA. Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. Journal of Leukocyte Biology. 60: 296-309. PMID 8830785 DOI: 10.1002/jlb.60.3.296  0.337
1996 Bartels CJ, Rosenberg SA, Yang JC. Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. Annals of Surgical Oncology. 3: 67-73. PMID 8770305 DOI: 10.1007/BF02409054  0.302
1996 Kawakami Y, Robbins PF, Rosenberg SA. Human melanoma antigens recognized by T lymphocytes. The Keio Journal of Medicine. 45: 100-8. PMID 8683899 DOI: 10.2302/Kjm.45.100  0.329
1996 Wang RF, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. The Journal of Experimental Medicine. 183: 1131-40. PMID 8642255 DOI: 10.1084/Jem.183.3.1131  0.309
1996 Yannelli JR, Hyatt C, McConnell S, Hines K, Jacknin L, Parker L, Sanders M, Rosenberg SA. Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience. International Journal of Cancer. Journal International Du Cancer. 65: 413-21. PMID 8621219 DOI: 10.1002/(SICI)1097-0215(19960208)65:4<413::AID-IJC3>3.0.CO;2-#  0.313
1995 Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ. CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion. Cancer Immunology, Immunotherapy : Cii. 40: 1-9. PMID 7828162 DOI: 10.1007/BF01517229  0.318
1994 Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proceedings of the National Academy of Sciences of the United States of America. 91: 3515-9. PMID 8170938 DOI: 10.1073/PNAS.91.9.3515  0.304
1994 Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute. 86: 1159-66. PMID 8028037 DOI: 10.1093/JNCI/86.15.1159  0.306
1994 Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proceedings of the National Academy of Sciences of the United States of America. 91: 9461-5. PMID 7937789 DOI: 10.1073/PNAS.91.20.9461  0.331
1994 Cohen PJ, Cohen PA, Rosenberg SA, Katz SI, Mulé JJ. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. European Journal of Immunology. 24: 315-9. PMID 7905414 DOI: 10.1002/eji.1830240206  0.333
1994 Shamamian P, Mancini M, Kawakami Y, Restifo NP, Rosenberg SA, Topalian SL. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest Cancer Immunology Immunotherapy. 39: 73-83. PMID 7519127 DOI: 10.1007/Bf01525312  0.325
1994 Salgaller ML, Weber JS, Koenig S, Yannelli JR, Rosenberg SA. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunology, Immunotherapy : Cii. 39: 105-16. PMID 7519125 DOI: 10.1007/BF01525316  0.311
1994 Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. International Journal of Cancer. 58: 69-79. PMID 7516926 DOI: 10.1002/IJC.2910580113  0.316
1994 Shilyansky J, Nishimura MI, Yannelli JR, Kawakami Y, Jacknin LS, Charmley P, Rosenberg SA. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proceedings of the National Academy of Sciences of the United States of America. 91: 2829-33. PMID 7511820 DOI: 10.1073/Pnas.91.7.2829  0.312
1993 Schwartzentruber DJ, Stetler-Stevenson M, Rosenberg SA, Topalian SL. Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation Blood. 82: 1204-1211. DOI: 10.1182/Blood.V82.4.1204.1204  0.308
1992 Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: Correlation with antigen presentation capability Journal of Experimental Medicine. 175: 1423-1431. PMID 1588273 DOI: 10.1084/Jem.175.6.1423  0.327
1992 Alexander RB, Bolton ES, Koenig S, Jones GM, Topalian SL, June CH, Rosenberg SA. Detection of antigen specific T lymphocytes by determination of intracellular calcium concentration using flow cytometry. Journal of Immunological Methods. 148: 131-41. PMID 1564323 DOI: 10.1016/0022-1759(92)90166-Q  0.312
1991 Aebersold P, Hyatt C, Johnson S, Hines K, Korcak L, Sanders M, Lotze M, Topalian S, Yang J, Rosenberg SA. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. Journal of the National Cancer Institute. 83: 932-7. PMID 2067036 DOI: 10.1093/JNCI/83.13.932  0.35
1990 Lotze MT, Custer MC, Bolton ES, Wiebke EA, Kawakami Y, Rosenberg SA. Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Human Immunology. 28: 198-207. PMID 2190952 DOI: 10.1016/0198-8859(90)90020-P  0.329
1988 Simpson C, Seipp CA, Rosenberg SA. The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment. Seminars in Oncology Nursing. 4: 132-41. PMID 3287538 DOI: 10.1016/0749-2081(88)90071-X  0.346
1988 Yang JC, Rosenberg SA. Current approaches to the adoptive immunotherapy of cancer Advances in Experimental Medicine and Biology. 233: 459-467. PMID 3265581 DOI: 10.1007/978-1-4899-5037-6_50  0.325
1988 Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. The New England Journal of Medicine. 319: 1676-80. PMID 3264384 DOI: 10.1056/NEJM198812223192527  0.362
1988 Rosenberg SA, Schwarz SL, Spiess PJ. Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2, alfa interferon, and tumor-infiltrating lymphocytes Journal of the National Cancer Institute. 80: 1393-1397. PMID 3262772 DOI: 10.1093/jnci/80.17.1393  0.309
1988 Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review Annals of Surgery. 208: 121-135. PMID 3041925 DOI: 10.1097/00000658-198808000-00001  0.337
1988 Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects Trends in Immunology. 9: 63. DOI: 10.1016/0167-5699(88)91261-3  0.325
1987 Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. Journal of Immunological Methods. 102: 127-41. PMID 3305708 DOI: 10.1016/S0022-1759(87)80018-2  0.302
1987 Skibber JM, Lotze MT, Uppenkamp I, Ross W, Rosenberg SA. Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. The Journal of Surgical Research. 42: 613-21. PMID 3295393 DOI: 10.1016/0022-4804(87)90004-7  0.311
1987 Topalian SL, Rosenberg SA. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2 Acta Haematologica. 78: 75-76. PMID 3124451 DOI: 10.1159/000205907  0.302
1985 Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. The New England Journal of Medicine. 313: 1485-92. PMID 3903508 DOI: 10.1056/NEJM198512053132327  0.319
1985 Rayner AA, Grimm EA, Lotze MT, Chu EW, Rosenberg SA. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer. Cancer. 55: 1327-33. PMID 3871657 DOI: 10.1002/1097-0142(19850315)55:6<1327::Aid-Cncr2820550628>3.0.Co;2-O  0.337
1985 Rayner AA, Grimm EA, Lotze MT, Wilson DJ, Rosenberg SA. Lymphokine-Activated Killer (LAK) Cell Phenomenon. IV. Lysis by LAK Cell Clones of Fresh Human Tumor Cells From Autologous and Multiple Allogeneic Tumors Journal of the National Cancer Institute. 75: 67-75. DOI: 10.1093/Jnci/75.1.67  0.301
1984 Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA. Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer. 53: 896-905. PMID 6692292 DOI: 10.1002/1097-0142(19840215)53:4<896::Aid-Cncr2820530414>3.0.Co;2-E  0.335
1983 Eberlein TJ, Rosenstein M, Spiess P, Wesley R, Rosenberg SA. Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor. Cancer Immunology, Immunotherapy : Cii. 13: 5-13. PMID 6984355 DOI: 10.1007/BF00200194  0.305
1983 Mazumder A, Grimm EA, Rosenberg SA. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization. Cancer Immunology, Immunotherapy : Cii. 15: 1-10. PMID 6603260 DOI: 10.1007/Bf00199454  0.315
1983 Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells Journal of Experimental Medicine. 157: 884-892. PMID 6601174 DOI: 10.1084/Jem.157.3.884  0.305
1982 Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. The Journal of Experimental Medicine. 155: 1823-41. PMID 6176669 DOI: 10.1084/Jem.155.6.1823  0.315
Show low-probability matches.